摘要
许多肿瘤,如神经内分泌肿瘤、甲状腺癌、乳腺癌等能高表达生长抑素受体,从而为生长抑素及其类似物的治疗提供了靶点。生长抑素受体介导的肿瘤靶向治疗主要包括放射性核素治疗、放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗。目前,生长抑素受体介导的放射性核素治疗已应用于神经内分泌肿瘤,尤其在胃肠胰神经内分泌肿瘤的诊断和治疗中占据重要地位。另外,生长抑素受体介导的放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗的潜在价值也越来越引起研究者们的重视。本文通过查阅近五年来关于生长抑素受体介导的肿瘤靶向治疗的国内外文献,综述了生长抑素受体介导的肿瘤靶向治疗的最新研究进展。
: A lot of tumors, such as neuroendocrine neoplasms, thyroid cancer and breast cancer usually can over express somatostatin receptors. Thus somatostatin and its analogues can target these tumors and exert anti-secretory activity and anti-neoplastic activity through binding to the somatostatin receptors on the surface of tumor cells. Somatostatin receptor-mediated tumor-targeted therapy mainly includes radionuclide therapy, radioguided surgery therapy, cytotoxic therapy and oncolytic virotherapy. Nowadays, somatostatin receptor-mediated radionuclide therapy have been put into use for the treatment of neuroendocrine neoplasms, especially playing an important role in the diagnosis and therapy of gastroenteropancreatic neuroendocrine neoplasms. Moreover, Somatostatin receptor-mediated radioguided surgery therapy, cytotoxic therapy and oncolytic virotherapy are also attracting more and more attention from researchers with the potential values in the treatment of various tumor types. In order to provide gist for the clinical applications of somatostatin receptor-mediated tumor-targeted therapy, the present article makes a review about up-to-date research advances of somatostatin receptor-mediated tumor-targeted therapy, informed by literatures about somatostatin receptor-mediated tumor-targeted therapy published at home or abroad in the past five years.
出处
《现代生物医学进展》
CAS
2016年第14期2793-2796,共4页
Progress in Modern Biomedicine
基金
湖南省自然科学基金项目(12JJ9030)